New drugs, screening tactics could nearly eliminate HCV by 2036

Hepatitis C accounts for a considerable economic burden for patients and the healthcare system, but the advent of new drugs and aggressive screening tactics could bring about a significant change.

Advertisement

Researchers at the University of Pittsburgh estimate that HCV could become a rare disease as early as 2036, according to a HCP Live report. The researchers based their prediction on the combination of HCV screening at birth and the use of new, direct-acting antiviral drugs.

The number of HCV patients in the United States has already significantly declined. In 2001, there were approximately 3.2 million cases in the country. The number dropped to 2.3 million cases in 2013, according to the report.

More articles on gastroenterology:
HCV outbreak confirmed at Tri-City Colonoscopy Clinic in Canada
Quest Diagnostics, CDC collaborate for hepatitis testing & treatment
3 GI/endoscopy devices receive FDA 510(k) clearance in January

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.